Edit
SciClone Pharmaceuticals
http://www.sciclone.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 08.11.2023
赛生药业,SciClone,赛生药业控股有限公司,SciClone Pharmaceuticals (Holdings) Limited
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 6
| Date | Title | Description | Source |
| 08.11.2023 | Menarini Group and SciClone Pharmaceuticals Announce Exclusi... | ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metast... | en.prnasia... |
| 20.09.2022 | Menarini and SciClone Sign Exclusive Licensing Agreement to ... | Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising pre... | en.prnasia... |
| 23.04.2021 | SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED SciClone Pharma... | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no respons... | marketscre... |
| 29.12.2020 | SciClone se incorpora al capital de AbilityPharma, participa... | 29/12/2020 Nota de prensa SCICLONE SE INCORPORA AL CAPITAL DE ABILITYPHARMA, PARTICIPADA POR INVER... | webcapital... |
| 17.10.2017 | Chinese consortium completes $605m buyout of Nasdaq-listed S... | Premium Nasdaq-listed SciClone Pharmaceuticals Inc. has been privatised and delisted from the New Y... | dealstreet... |
| 08.06.2017 | Term Sheet — Thursday, June 8 | You’ll Laugh! Cry! (Maybe Buy.) Below is my column from the latest issue of Fortune. Apologies if t... | fortune.co... |